

Policy for Discontinuing Regimens that Do Not Include a Rifamycin

Virginia Department of Health, Division of TB and Newcomer Health

Purpose: To assure TB cases who are resistant or intolerant to a rifamycin complete a sufficient regimen before treatment is discontinued.

Notification Requirements:

1. Local health districts (LHD) should notify the Division of Tuberculosis and Newcomer Health (DTBNH) as soon as susceptibility results (either molecular or traditional) demonstrate resistance to any rifamycin.
2. LHDs should notify DTBNH as soon as a rifamycin is permanently discontinued due to toxicity

Consultation with one of the DTBNH expert clinical consultants is required for all individuals undergoing treatment for active or suspected TB whose regimen does not include a rifamycin. Contact the DTBNH (804-864-7906) to begin consultation.

Approval of treatment completion requirements:

1. **4 weeks prior to expected treatment completion** fax (804-371-0248) a brief treatment summary, including Directly Observed Therapy (DOT) records, for all active TB cases who are diagnosed with
 - multi-drug resistant TB (MDRTB),
 - extremely drug resistant TB (XDRTB)
 - poly-resistant drug resistant TB that excludes a rifamycin from the regimen
 - intolerance to a rifamycin for all or any part of a treatment course
2. The case information will be reviewed by one of the Virginia Department of Health (VDH) TB Clinical Consultants and the Director of TB Control.
3. This policy applies to all TB cases including those managed by private providers; those managed by local health departments; or those co-managed by private providers and local health departments.
4. Treatment can be discontinued after a thorough review of the case has been completed. A written approval will be provided by the TB Control Director.